Ibrutinib-related uveitis: A case series from two tertiary centres in the United Kingdom
Purpose
Ibrutinib is a Bruton’s tyrosine kinase inhibitor that is licensed for treatment of low-grade B-cell malignancies. A Few case reports in the literature suggest that uveitis may be a side effect of ibrutinib treatment.
Methods
We report nine cases of ibrutinib-related uveitis from two tertiary centres in the United Kingdom.
Results
In our case series, uveitis appears to be a type D, or delayed drug reaction of ibrutinib. The uveitis can be anterior, intermediate, posterior or panuveitis and associated with cystoid macular oedema. It can range in severity from mild, to severe and vision threatening.
Conclusion
Ibrutinib related uveitis appears to be more common than previously recognised.
Conflict of interest
No
Authors 1
Last name
IBRAHIM
Initials of first name(s)
H
Department
St Paul’s Eye Unit, Liverpool University Hospitals NHS Trust
City
Liverpool
Country
United Kingdom
Authors 2
Last name
Kalakonda
Initials of first name(s)
AJM
Department
Clatterbridge Cancer Centre NHS Trust
City
Liverpool
Country
United Kingdom
Authors 3
Last name
Chean
Initials of first name(s)
CS
Department
University Hospitals of Leicester NHS Trust
City
Leicester
Country
United Kingdom
Authors 4
Last name
Kwan
Initials of first name(s)
J
Department
University Hospitals of Leicester NHS Trust
City
Leicester
Country
United Kingdom
Authors 5
Last name
Kumar
Initials of first name(s)
P
Department
University Hospitals of Leicester NHS Trust
City
Leicester
Country
United Kingdom
Authors 6
Last name
Williams
Initials of first name(s)
S
Department
Clatterbridge Cancer Centre NHS Trust
City
Liverpool
Country
United Kingdom
Authors 7
Last name
Beare
Initials of first name(s)
NAV
Department
St Paul’s Eye Unit, Liverpool University Hospitals NHS Trust
City
Liverpool
Country
United Kingdom
This website uses cookies to ensure you get the best experience on our website.
Learn more